Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHZORA High study of ozoralizumab in rheumatoid arthritis by rheumatoid factor titer
jRCTs051240053Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of ozoralizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: DAS28-CRP at 12 weeks. Started Aug 2024; status: recruiting.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs051240053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240053.